Corvus Pharmaceuticals, Inc. (CRVS)Healthcare | Biotechnology | South San Francisco, United States | NasdaqGM
14.71 USD
-0.96
(-6.126%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 14.66 -0.05 (-0.050%) ⇩ (July 13, 2026, 7:59 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 3:34 a.m. EDT
The immediate outlook is bullish due to a confluence of technical breakouts and heavy speculative positioning. The stock has rallied significantly over the last two weeks, approaching the $16 psychological barrier where options data reveals a dense wall of open interest and volume. This suggests smart money is betting on a catalyst to push the price higher. However, the long-term picture remains precarious; despite a recent surge in share price, the company has endured nearly a decade of cumulative losses and negative returns on equity. The balance sheet is technically clean with minimal debt, but the business burns cash, and the lack of dividends reflects its speculative nature. Investors should view this as a high-risk momentum play on a potential clinical or commercial milestone rather than a stable investment in a profitable enterprise. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.133069 |
| AutoARIMA | 0.133435 |
| MSTL_60 | 0.140024 |
| MSTL | 0.149176 |
| AutoTheta | 0.149543 |
| MSTL_60_97 | 0.193227 |
| MSTL_97 | 0.204568 |
Forecast horizon: 60 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 28% |
| H-stat | 7.88 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.073 |
| Excess Kurtosis | -1.44 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.347 |
| Market Cap | 1,236,970,112 |
| Forward P/E | -15.54 |
| Beta | 0.82 |
| Website | https://www.corvuspharma.com |
As of July 11, 2026, 3:34 a.m. EDT: Speculators are aggressively positioning for a breakout above the $16 strike, evidenced by massive open interest walls and volume spikes in both calls and puts at that level. The implied volatility surface shows elevated premiums for out-of-the-money strikes, suggesting a binary event or catalyst is priced in. While put writers are active at lower strikes, the sheer density of call buying at the $16 barrier indicates a consensus expectation of a sharp upward move if the stock clears this technical resistance.
| Attribute | Value |
|---|---|
| 52 Week Change | 2.6022987 |
| Address1 | 901 Gateway Boulevard |
| Address2 | Third Floor |
| All Time High | 26.95 |
| All Time Low | 0.607 |
| Ask | 18.85 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Daily Volume10 Day | 1,714,810 |
| Average Daily Volume3 Month | 1,588,229 |
| Average Volume | 1,588,229 |
| Average Volume10Days | 1,714,810 |
| Beta | 0.817 |
| Bid | 10.98 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 2.862 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 14.71 |
| Current Ratio | 19.814 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 15.585 |
| Day Low | 14.69 |
| Debt To Equity | 0.347 |
| Display Name | Corvus Pharmaceuticals |
| Earnings Call Timestamp End | 1,773,347,400 |
| Earnings Call Timestamp Start | 1,773,347,400 |
| Earnings Timestamp | 1,778,184,000 |
| Earnings Timestamp End | 1,786,046,400 |
| Earnings Timestamp Start | 1,786,046,400 |
| Ebitda | -47,814,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -20.937 |
| Enterprise Value | 1,001,090,112 |
| Eps Current Year | -0.71667 |
| Eps Forward | -0.94667 |
| Eps Trailing Twelve Months | -0.55 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 13.4767 |
| Fifty Day Average Change | 1.2333002 |
| Fifty Day Average Change Percent | 0.091513515 |
| Fifty Two Week Change Percent | 260.22986 |
| Fifty Two Week High | 26.95 |
| Fifty Two Week High Change | -12.240001 |
| Fifty Two Week High Change Percent | -0.4541744 |
| Fifty Two Week Low | 3.96 |
| Fifty Two Week Low Change | 10.75 |
| Fifty Two Week Low Change Percent | 2.7146463 |
| Fifty Two Week Range | 3.96 - 26.95 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,458,739,800,000 |
| Float Shares | 72,758,398 |
| Forward Eps | -0.94667 |
| Forward P E | -15.538678 |
| Free Cashflow | -22,572,750 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 37 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03509 |
| Held Percent Institutions | 0.85555 |
| Implied Shares Outstanding | 84,090,424 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of first line renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1 clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as license agreement with Scripps for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California. |
| Long Name | Corvus Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 1,236,970,112 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_279359732 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -44,168,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,317,696,944 |
| Number Of Analyst Opinions | 6 |
| Open | 15.28 |
| Operating Cashflow | -34,908,000 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 650 900 4520 |
| Post Market Change | -0.05000019 |
| Post Market Change Percent | -0.33990613 |
| Post Market Price | 14.66 |
| Post Market Time | 1,783,987,169 |
| Previous Close | 15.67 |
| Price Eps Current Year | -20.525486 |
| Price Hint | 2 |
| Price To Book | 5.1397624 |
| Profit Margins | 0.0 |
| Quick Ratio | 19.646 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.96 |
| Regular Market Change Percent | -6.12636 |
| Regular Market Day High | 15.585 |
| Regular Market Day Low | 14.69 |
| Regular Market Day Range | 14.69 - 15.585 |
| Regular Market Open | 15.28 |
| Regular Market Previous Close | 15.67 |
| Regular Market Price | 14.71 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 1,453,074 |
| Return On Assets | -0.19162 |
| Return On Equity | -0.3046 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 84,090,424 |
| Shares Percent Shares Out | 0.22379999 |
| Shares Short | 18,819,891 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 17,324,311 |
| Short Name | Corvus Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.2544 |
| Short Ratio | 13.43 |
| Source Interval | 15 |
| State | CA |
| Symbol | CRVS |
| Target High Price | 42.0 |
| Target Low Price | 27.0 |
| Target Mean Price | 33.33333 |
| Target Median Price | 31.5 |
| Total Cash | 236,714,000 |
| Total Cash Per Share | 2.815 |
| Total Debt | 834,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.55 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 12.44285 |
| Two Hundred Day Average Change | 2.26715 |
| Two Hundred Day Average Change Percent | 0.18220504 |
| Type Disp | Equity |
| Volume | 1,453,074 |
| Website | https://www.corvuspharma.com |
| Zip | 94,080 |